Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity Cancer
NCT ID: NCT05049408
Last Updated: 2021-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1160 participants
OBSERVATIONAL
2011-02-17
2016-12-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell Carcinoma
NCT05821179
Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity
NCT05791149
Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer
NCT01587573
Biomarkers in Tissue Samples From Patients Who Have Undergone Neck Dissection for Oral Cancer
NCT00899704
Toluidine Blue Versus Frozen Sections for Assessment of Tumor Margins in Oral Squamous Cell Carcinoma
NCT03554967
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group OSCC
Patients with Oral Squamous Cell Carcinoma (OSCC)
MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
The MMP-1 ELISA is to measure salivary MMP-1 levels of participants
Group OPMD
Patients with oral potentially malignant disorders (OPMD)
MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
The MMP-1 ELISA is to measure salivary MMP-1 levels of participants
Group HC
Healthy Control
MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
The MMP-1 ELISA is to measure salivary MMP-1 levels of participants
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
The MMP-1 ELISA is to measure salivary MMP-1 levels of participants
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Group OPMD: patients with lesions of OPMD
* Group HC: healthy subjects who are not suffering from any oral lesions and having behaviors of smoking, and/or betel nut chewing
Exclusion Criteria
20 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
S&T Biomed Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, , Taiwan
Chi-Mei Medical Center
Tainan City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Chang YT, Chu LJ, Liu YC, Chen CJ, Wu SF, Chen CH, Chang IY, Wang JS, Wu TY, Dash S, Chiang WF, Chiu SF, Gou SB, Chien CY, Chang KP, Yu JS. Verification of Saliva Matrix Metalloproteinase-1 as a Strong Diagnostic Marker of Oral Cavity Cancer. Cancers (Basel). 2020 Aug 13;12(8):2273. doi: 10.3390/cancers12082273.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STBM-CT-OSCC-DIA001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.